10649301

=> d his

(FILE 'HOME' ENTERED AT 11:47:49 ON 14 MAY 2004)

FILE 'REGISTRY' ENTERED AT 11:48:01 ON 14 MAY 2004
L1 STRUCTURE UPLOADED
L2 4 S L1
L3 58 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:49:08 ON 14 MAY 2004
L4 6 S L3

FILE 'MARPAT' ENTERED AT 11:50:15 ON 14 MAY 2004
L5 0 S L3
L6 9 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:50:41 ON 14 MAY 2004
L7 9 S L6

=> s l7 not l4
L8 4 L7 NOT L4

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 1-4 bib abs

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:202648 CAPLUS
DN **138:238160**
TI Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents
IN Thorarensen, Atli
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020730	A1	20030313	WO 2002-US27738	20020829
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003100536	A1	20030529	US 2002-230891	20020829
PRAI	US 2001-316129P	P	20010830		

OS MARPAT 138:238160
GI



I



II

AB The title compds. [I; R1 = Cl, Br, CN, NO2, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, atherosclerosis or restenosis, were prepared Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC50 of 0.91 μM, 0.36 μM and 0.13 μM against HCMV, HSV and VZV polymerases, resp.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:202647 CAPLUS
DN **138:238159**
TI Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
IN Thorarensen, Atli
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020729	A1	20030313	WO 2002-US27527	20020829
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003109542	A1	20030612	US 2002-230890	20020829
	US 6620810	B2	20030916		
PRAI	US 2001-316108P	P	20010830		

OS MARPAT 138:238159
GI



I



II

AB The title compds. [I; R1 = Cl, Br, CN, NO2, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, atherosclerosis or restenosis, were prepared Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded 37% I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC50 of 0.63 μM, 0.16 μM and 0.08 μM against HCMV, HSV and VZV polymerases, resp.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:202646 CAPLUS
DN **138:238158**
TI Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents
IN Thorarensen, Atli
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020728	A1	20030313	WO 2002-US25858	20020814
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003100536	A1	20030529	US 2002-230891	20020829
PRAI	US 2001-316129P	P	20010830		

OS MARPAT 138:238158
GI



I



II

AB The title compds. [I; R1 = Cl, Br, CN, NO2, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, atherosclerosis or restenosis, were prepared Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC50 of 0.91 μM, 0.36 μM and 0.13 μM against HCMV, HSV and VZV polymerases, resp.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51456 CAPLUS
DN **136:118476**
TI Preparation of heterocycle carboxamides as antiviral agents
IN Bundy, Gordon L.; Ciske, Fred L.; Genin, Michael J.; Heasley, Steven E.; Larsen, Scott D.; Lee, Byung Hyun; May, Paul D.; Palmer, John R.; Schnute, Mark E.; Vaillancourt, Valerie A.; Thorarensen, Atli; Wolf, Allison J.; Wicnienski, Nancy Anne; Wilhite, David
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004444	A2	20020117	WO 2001-US16495	20010625
	WO 2002004444	A3	20020530		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002025960	A1	20020228	US 2001-887794	20010622
	US 6559145	B2	20030506		
	EP 1301493	A2	20030416	EP 2001-948227	20010625
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004502770	T2	20040129	JP 2002-509309	20010625
	US 2003207880	A1	20031106	US 2002-323027	20021218
PRAI	US 2000-217558P	P	20000712		
	US 2001-272142P	P	20010228		
	US 2001-887794	A3	20010622		
	WO 2001-US16495	W	20010625		

OS MARPAT 136:118476
GI



I



II

AB The title compds. [I; X = Cl, Br, F, CN, NO2; G = alkyl which is fully saturated or partially unsatd. and is substituted by OH, or alkyl substituted by NR1R2 or 4-tetrahydropyran; R1 = alkyl substituted by OH, alkoxy, heteroaryl or aryl; R2 = H, alkyl; NR1R2 = (un)substituted morpholine, pyrrolidine substituted by OH; W = pyridopyrimidine, thiazolopyrimidine, benzothiadiazine, etc.], useful as antiviral agents, in particular, as agents against viruses of the herpes family, were prepared Thus, alkylation of N-(4-chlorophenyl)-7-iodo-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide (preparation given) with propargyl alc. in the presence of PdCl2(PPh3)2 and Et3N in DMF afforded 58% II.

10649301

=> d his

(FILE 'HOME' ENTERED AT 11:47:49 ON 14 MAY 2004)

FILE 'REGISTRY' ENTERED AT 11:48:01 ON 14 MAY 2004
L1 STRUCTURE UPLOADED
L2 4 S L1
L3 58 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:49:08 ON 14 MAY 2004
L4 6 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 1-6 bib abs hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:220341 CAPLUS
DN 140:270842
TI Preparation of arylethanol(thienopyridinemethyl)amine derivatives as antiviral agents
IN Schnute, Mark E.; Cudahy, Michele M.; Ciske, Fred L.; Genin, Michael J.; Anderson, David J.; Judge, Thomas M.; Eggen, Marijean; Collier, Sarah A.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022568	A1	20040318	WO 2003-US24807	20030827

PI W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-408206P P 20020904
OS MARPAT 140:270842
GI



I



II

AB Arylethanol(thienopyridinemethyl)amine derivs. of formula I [R1 = halo, CN; R2 = (substituted) alkyl, etc.; R3 = alkyl; R4 = H, (substituted) alkyl; Ar = (substituted) Ph, aryl] are prepared as antiviral agents, in particular, as agents against viruses of the herpes family. Thus, II was prepared, and had IC50 of 0.05 μM against HCMV polymerase.

IT **672325-77-8P 672325-86-9P 672325-93-8P**
672325-95-0P 672325-97-2P 672325-98-3P
672325-99-4P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)

RN 672325-77-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672325-86-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(3-methoxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672325-93-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-(4-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-

4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672325-95-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-(3-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672325-97-2 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-[4-(dimethylamino)phenyl]-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672325-98-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-[4-(hydroxymethyl)phenyl]ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672325-99-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-nitrophenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **672325-79-0P 672325-81-4P 672325-82-5P**
672325-84-7P 672325-88-1P 672325-90-5P
672325-91-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)

RN 672325-79-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672325-81-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672325-82-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672325-84-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672325-88-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672325-90-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672325-91-6 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **292144-13-9**
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)
RN 292144-13-9 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT **672326-38-4P 672326-39-5P 672326-40-8P**
672326-41-9P 672326-42-0P 672326-43-1P
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)
RN 672326-38-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-methoxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-39-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(4-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-40-8 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(3-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-41-9 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-[4-(dimethylamino)phenyl]-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-42-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-[4-(hydroxymethyl)phenyl]ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 672326-43-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-nitrophenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT **672326-26-0P 672326-28-2P 672326-29-3P**
672326-30-6P 672326-32-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)

RN 672326-26-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672326-28-2 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672326-29-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672326-30-6 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[(methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-32-8 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-[4-(dimethylamino)phenyl]-2-oxoethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:220340 CAPLUS
DN 140:270841
TI Preparation of heteroarylethanolamines as antiviral agents
IN Fleck, Thomas J.; Schnute, Mark E.; Cudahy, Michele M.; Anderson, David J.; Judge, Thomas M.; Herrington, Paul M.; Nair, Sajiv K.; Scott, Allen; Perrault, William R.; Tanis, Steven P.; Nieman, James A.; Collier, Sarah A.
PA Pharmacia & Upjohn Company, USA; Fleck, Bruce Francis
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022567	A1	20040318	WO 2003-US24806	20030827

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-408065P P 20020904
OS MARPAT 140:270841
GI



I

AB Title compds. [I; R1 = Cl, Br, F, cyano; R2 = alkyl, hydroxyalkyl, alkoxyalkyl, (CH2)mOCH2CH2OH; m = 1, 2; R3 = alkyl; R4 = (R6-substituted) (benzo-fused) C-bonded 6-membered heteroaryl containing 1-3 N atoms; R5 = H, alkyl, hydroxyalkyl; R6 = halo, OCF3, cyano, NO2, CONR7R8, NR7R8, OR10, CO2R10, (unsatd.) (R9-substituted) alkyl, etc.; R7, R8 = H, (substituted) Ph, alkyl, cycloalkyl, etc.; R9 = O, OR10, SR10, halo, NR7R8, CO2R10, etc.; R10 = H, alkyl, cycloalkyl, (substituted) Ph], were prepared Thus, N-(4-chlorobenzyl)-2-(chloromethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (preparation given), diisopropylethylamine, and 2-(methylamino)-1-pyridin-3-ylethanol hydrobromide were heated in DMF at 90° for 2 h to give N-(4-chlorobenzyl)-2-[[(2-hydroxy-2-pyridin-3-ylethyl)(methyl)amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide. The latter inhibited HCMV, HSV, and VSV polymerase with IC50 = 0.16, 0.58, and 0.22 μM, resp.

IT **672949-14-3P**

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylethanolamines as antiviral agents)

RN 672949-14-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



IT **672949-12-1P 672949-16-5P 672949-18-7P**
672949-20-1P 672949-22-3P 672949-24-5P
672949-26-7P 672949-28-9P 672949-30-3P
672949-32-5P 672949-34-7P 672949-36-9P
672949-38-1P 672949-40-5P 672949-42-7P
672949-44-9P 672949-46-1P 672949-48-3P
672949-50-7P 672949-52-9P 672949-54-1P
672949-57-4P 672949-59-6P 672949-61-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylethanolamines as antiviral agents)

RN 672949-12-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-16-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-18-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-20-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672949-22-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(6-methyl-2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-24-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-

dihydro-2-[[[2-hydroxy-2-(2-quinolinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-26-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-28-9 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672949-30-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[(2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-32-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-34-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-pyridazinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-36-9 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[[(2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-38-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-40-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)



RN 672949-42-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[(2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)



RN 672949-44-9 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-46-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-48-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-50-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-52-9 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[(2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-54-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-[2-(2-hydroxyethoxy)ethyl]-2-[[[(2R)-2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-57-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-fluorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672949-59-6 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-cyanophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672949-61-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **672950-41-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroarylethanolamines as antiviral agents)
RN 672950-41-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(dimethylamino)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT **672326-30-6P 672950-21-9P 672950-23-1P**
672950-25-3P 672950-27-5P 672950-29-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroarylethanolamines as antiviral agents)

RN 672326-30-6 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[(methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672950-21-9 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[[methyl(2-oxo-2-pyrazinylethyl)amino]methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672950-23-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672950-25-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672950-27-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 672950-29-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:203665 CAPLUS
DN 140:229446
TI Method using heterocyclic carboxamide compounds for preventing or treating atherosclerosis or restenosis
IN Wathen, Michael W.; Wathen, Lynne K.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019939	A1	20040311	WO 2003-US26973	20030828

PI
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-407090P P 20020830
OS MARPAT 140:229446
AB The invention provides a method of treating atherosclerosis or restenosis in a mammal which comprises administering an effective amount of a thieno[2,3-b]pyridine carboxamide derivative or a pyrrolo[3,2,1-ij]quinoline carboxamide derivative
IT **292144-13-9 292144-14-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic carboxamide compds. for preventing or treating atherosclerosis or restenosis)
RN 292144-13-9 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-14-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[(2-hydroxy-2-phenylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

10649301

AN 2004:203660 CAPLUS
DN 140:229445
TI Method using heterocyclic carboxamides for preventing or treating atherosclerosis or restenosis
IN Wathen, Michael W.; Wathen, Lynne K.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019933	A1	20040311	WO 2003-US26963	20030828

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-407563P P 20020830
US 2003-469630P P 20030509
OS MARPAT 140:229445
AB The invention provides a method of preventing or treating atherosclerosis or restenosis in mammals, which comprises administering an effective amount of a heterocyclic carboxamide.
IT **292144-14-0**
RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic carboxamides for preventing or treating atherosclerosis or restenosis)
RN 292144-14-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[(2-hydroxy-2-phenylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:72315 CAPLUS
DN 136:129036
TI Method of screening 4-hydroxyquinolin (4-HQ), 4-oxo-dihydroquinoline (4-oxo-DHQ), and 4-oxo-dihydrothienopyridine (4-oxo-DHTP) derivatives as non-nucleoside herpesvirus DNA polymerase inhibitor
IN Homa, Fred L.; Wathen, Michael W.; Hopkins, Todd A.; Thomsen, Darrel R.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002006513	A2	20020124	WO 2001-US16525	20010713
	WO 2002006513	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002076789 A1 20020620 US 2001-904065 20010712
US 6682892 B2 20040127
PRAI US 2000-218118P P 20000713
US 2001-283880P P 20010413

AB The present invention provides a method for selecting non-nucleoside herpesvirus DNA polymerase inhibitors from 4-HQ, 4-oxo-DHQ, and 4-oxo-DHTP derivs. by measuring IC50. The invention also provides sequences of mutant herpesvirus DNA polymerase genes which resist non-nucleoside inhibitors, and herpesvirus mutant strains containing the drug-resistant DNA polymerase genes. The present invention relates to a method for selecting an anti-herpes viral compound and a method for selectively inhibiting herpesvirus in a human host in need of such treatment. The present invention relates to a method for selecting an anti-herpes viral compound and a method for selectively inhibiting herpesvirus in a human host in need of such treatment.

IT **292144-14-0**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(4-HQ,4-oxo-DHQ, and 4-oxo-DHTP derivs. as non-nucleoside herpesvirus DNA polymerase inhibitor)

RN 292144-14-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[(2-hydroxy-2-phenylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:646018 CAPLUS
DN 133:222607
TI Preparation of 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
IN Schnute, Mark E.; Cudahy, Michele M.; Scott, Allen
PA Pharmacia and Upjohn Company, USA
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000053610	A2	20000914	WO 2000-US5937	20000307
WO 2000053610	A3	20010125		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6239142	B1	20010529	US 2000-521027	20000307
NZ 513758	A	20010928	NZ 2000-513758	20000307
EP 1159279	A2	20011205	EP 2000-913786	20000307
EP 1159279	B1	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008804	A	20020416	BR 2000-8804	20000307

	AT 226208	E	20021115	AT 2000-913786	20000307
	JP 2002539130	T2	20021119	JP 2000-604046	20000307
	ES 2184705	T3	20030416	ES 2000-913786	20000307
	AU 759875	B2	20030501	AU 2000-35162	20000307
	AU 2000035162	A5	20000928		
	US 2002006937	A1	20020117	US 2001-824334	20010402
	US 6495683	B2	20021217		
	ZA 2001007255	A	20021202	ZA 2001-7255	20010831
	NO 2001004363	A	20011108	NO 2001-4363	20010907
PRAI	US 1999-123660P	P	19990309		
	US 2000-521027	A3	20000307		
	WO 2000-US5937	W	20000307		

OS MARPAT 133:222607

GI



I

AB The title compds. [I; R1 = Cl, Br, CN, etc.; R2 = H, R5, NR7R8, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.; R5 = heterocyclyl bound via a carbon atom, (un)saturated (un)substituted alkyl, (un)saturated (un)substituted cycloalkyl, etc.; R7, R8 = H, aryl, (un)saturated (un)substituted alkyl; NR7R8 form a heterocyclyl] and their pharmaceutically acceptable salts, useful in preventing or treating a herpesvirus infection, were prepared Thus, reacting Et 4-hydroxythieno[2,3-b]pyridine-5-carboxylate with 4-chlorobenzylamine afforded 45% I [R1 = Cl; R2 = H; R3, R4 = H] which showed IC50 of 28.9 μM against HCMV polymerase.

IT **292144-13-9P 292144-14-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents)

RN 292144-13-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-14-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[(2-hydroxy-2-phenylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)